TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US

 

 

 

 

 

Home Page  |  

 

November 30 , 2006
PRESS RELEASE 

PEGASUS/HEARTVIEW'S SCREENING DEVICE FOR HEART DISEASE RECEIVES MARKETING APPROVAL FOR EUROPEAN UNION.

Palm Beach Gardens , FL , Market Wire, November 30 th , 2006. Pegasus/HeartView LLC (Symbol: PGUZ-OTC) today announced that they have received a CE Mark Approval for the marketing of their 6S Screening Device in Europe . The CE Mark Approval authorizes Pegasus to commence a comprehensive marketing effort throughout Europe and many other countries, which recognize the CE Mark Approval.  

In November, Pegasus/HeartView LLC participated with one of its OEM European manufacturers in the world's largest medical trade fair, the MEDICA 2006 SHOW, in Dusseldorf, Germany (November 14 th to 17 th , 2006). Pegasus/HeartView demonstrated the 6S Heart Screening Device to hundreds of medical professionals and met with several potential European distributors who will participate in the marketing launch of the device, which is an advanced, rapid and accurate screening technology for early, non-invasive detection of heart disease.

For more information, please contact Paul Davey, Investor Services at (778) 389-0915
( Canada ). Email: paul@pegasusbiosciences.com, or Daniel P. Kesonen, Chairman & CEO of Pegasus Pharmaceuticals Inc., Palm Beach Florida at (561) 626-9901.

Safe Harbor :
This news release may include forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United states Securities and Exchange Act of 1934, as amended with respect to achieving corporate objectives, developing additional project interests, the Company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. These statements are made under the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements herein.

 


Copyright © 2006, Pegasus Pharmaceuticals Inc.